Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
Short descriptor: Tixagev and cilgav, 300mg
Look up Q0220 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
Q0220 is the HCPCS Level II code for Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg (2026). It belongs to Section Q — Temporary Codes. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Vaccinations.
Classification & CMS Attributes
- Section
- Q: Temporary Codes
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Vaccinations (indicator 54)
- Type of Service
- Pneumococcal/flu/hepatitis B vaccine
- Effective Date
- 2024-12-13
- Termination Date
- 2024-12-12
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference Q0220 with the canonical source and edition:
Q0220 — Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/Q0220
Canonical URL: https://icd10codingpro.com/hcpcs-codes/Q0220